Form 4: Y-mAbs Therapeutics CFO Peter Pfreundschuh Reports Stock and Option Grants
SEC Form 4 Filing
Peter Pfreundschuh, CFO and Treasurer of Y-mAbs Therapeutics, reports the acquisition of restricted stock units and stock options.
Summary
- Peter Pfreundschuh, CFO and Treasurer of Y-mAbs Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On July 12, 2024, Pfreundschuh was granted 46,000 restricted stock units (RSUs) and 170,000 stock options under the company's 2018 Equity Incentive Plan.
- The RSUs vest in three equal installments on July 12, 2025, July 12, 2026, and July 12, 2027, contingent upon continued service.
- The stock options vest as to 25% on July 12, 2025, and then in equal monthly installments until fully vested, also contingent upon continued service.
Sentiment
Score: 7
Explanation: The document reflects a standard equity grant, which is generally viewed positively as it aligns management interests with shareholders. The vesting schedule promotes long-term commitment.
Positives
- The grant of RSUs and stock options aligns the CFO's interests with those of the shareholders.
- Vesting schedules tied to continued service incentivize long-term commitment from the CFO.
Industry Context
Equity grants are a common practice in the biopharmaceutical industry to attract and retain key executives, aligning their interests with the long-term success of the company.
Comparison to Industry Standards
- Equity compensation packages for CFOs in the biopharmaceutical industry typically include a mix of stock options and restricted stock units.
- The vesting schedules are generally structured to incentivize long-term performance and retention, often over a threeto four-year period.
- The size of the grant is generally based on the CFO's role, responsibilities, and overall contribution to the company's strategic goals.
Stakeholder Impact
- Shareholders may view the equity grants positively as they incentivize management to increase shareholder value.
- Employees may see the grants as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 07/12/2024 | Date of transaction: Grant of RSUs and stock options. |
| 07/12/2025 | First vesting date for 1/3 of RSUs and 25% of stock options. |
| 07/12/2026 | Second vesting date for 1/3 of RSUs. |
| 07/12/2027 | Final vesting date for 1/3 of RSUs. |
| 07/12/2034 | Expiration date of stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.